Praxis Precision Medicines, Inc. (PRAX) stock
Close on Nov 12, 2026Market cap $9.07BP/E –Yield –
Praxis Precision Medicines, Inc. saw revenue fall 100.0% to $0 over fiscal 2025. Free cash flow was -$323.62M. At the latest close the market valued the company at $9.07B.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Sep 30, 2026
Valuation
- Market cap
- $9.07B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 7.20
- Dividend yield
- –
- Free cash flow yield
- -3.57%
Fundamentals
- Revenue
- $0
- Net income
- -$359.43M
- EPS, diluted
- -$12.79
- Free cash flow
- -$323.62M
- Book value per share
- $43.17
- Diluted shares
- 29M
Trading
- Next earnings
- Feb 18, 2027 (estimated, before the open)
- Previous close
- $346.21
- Open
- $342.38
- Day's range
- $319.24 – $343.71
- Volume
- 590,079
- Average volume (20 days)
- 499,770
- Index membership
- Russell 2000 (since Sep 2024), Russell 3000 (since Aug 2024)
- Beta (5 years)
- 1.64
- 52-week range
- $160.11 – $392.70
- RSI (14 days)
- 60.6
- Volatility (1 year)
- 75.0%
- Relative volume
- 1.35×
- WACC
- 13.1%
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | PRAX | S&P 500 | Difference | PRAX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +29.2% | -2.7% | +31.9 pts | ||
| 3 months | -15.9% | -1.7% | −14.2 pts | ||
| Year to date | +10.2% | +11.9% | −1.7 pts | ||
| 1 year | +76.9% | +12.0% | +64.9 pts | ||
| 3 years | +2109.4% | +78.2% | +2031.2 pts | +180.6% | +21.2% |
| 5 years | +6.6% | +73.2% | −66.7 pts | +1.3% | +11.6% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Praxis Precision Medicines filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Praxis Precision Medicines
Pharmaceutical Preparations
The biopharmaceutical company specializes in developing precision therapies for central nervous system (CNS) disorders caused by imbalances in neuronal excitation and inhibition. Leveraging human genetic insights from epilepsies, the enterprise discovers and develops therapies using two proprietary platforms: Cerebrum, which focuses on small molecules, and Solidus, an antisense oligonucleotide engine. Its primary clinical-stage pipeline comprises small molecule candidates such as ulixacaltamide, vormatrigine, and relutrigine, as well as the oligonucleotide candidate elsunersen. The company creates these targeted therapeutics for individuals diagnosed with movement disorders, such as essential tremor, alongside severe genetic conditions like developmental and epileptic encephalopathies and common adult epilepsies.
Company profile, executives and historyPraxis Precision Medicines stock: common questions
What is Praxis Precision Medicines's stock price?
PRAX closed at $324.76 on Nov 12, 2026, down 6.20% on the day. Over the past 52 weeks it traded between $160.11 and $392.70.
What is Praxis Precision Medicines's market cap?
Praxis Precision Medicines was worth $9.07B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is PRAX's P/E ratio?
Praxis Precision Medicines lost money over the twelve months to Sep 30, 2026 (diluted EPS -$12.79), so it has no meaningful P/E ratio.
How much revenue does Praxis Precision Medicines make?
Praxis Precision Medicines reported revenue of $0 for fiscal 2025, down 100.0% from a year earlier.
Does Praxis Precision Medicines pay a dividend?
No. Praxis Precision Medicines has not paid a cash dividend over the last twelve months.
When does Praxis Precision Medicines report earnings next?
Praxis Precision Medicines is expected to report Q4 FY2026 results on Feb 18, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has PRAX stock performed over the past year?
Including dividends, PRAX returned +76.9% over the past year, against +12.0% for the S&P 500.
How many PRAX shares are sold short?
4M shares were sold short at the latest FINRA report, 15.18% of the float, or 8.7 days of average trading volume.
Who are Praxis Precision Medicines's competitors?
Companies most similar to Praxis Precision Medicines by business, industry and size include XENE, CAMP, TRDA, ALMS, ACIU.
See a number that looks wrong?